SCHEMBL5833688

SCHEMBL5833688

COc1cc(CCO)cc(OC)c1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.64
HTR2C P28335 1/20 0.64
HTR2B P41595 1/20 0.64
PTGS2 P35354 1/20 0.59
TUBB4A P04350 4/20 0.58
TUBB P07437 4/20 0.58
TUBA3C P0DPH7 4/20 0.58
TUBA1B P68363 4/20 0.58
TUBA4A P68366 4/20 0.58
TUBB4B P68371 4/20 0.58
TUBB3 Q13509 4/20 0.58
TUBB2A Q13885 4/20 0.58
TUBB8 Q3ZCM7 4/20 0.58
TUBA3E Q6PEY2 4/20 0.58
TUBA1A Q71U36 4/20 0.58
TUBA1C Q9BQE3 4/20 0.58
TUBB6 Q9BUF5 4/20 0.58
TUBB2B Q9BVA1 4/20 0.58
TUBB1 Q9H4B7 4/20 0.58
AOC3 Q16853 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11039976 0.89 CA12 (0.58) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL2007007 0.88 TNKS2 (0.68) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL7378487 0.87 HTR2A (0.50) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL4464142 0.86 HTR2A (0.75) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL23266383 0.86 TUBB1 (0.63) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL7376461 0.85 HTR2A (0.49) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL4740186 0.84 TUBB4A (0.61) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL30504713 0.83 HTR2A (0.55) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL4035285 0.83 HTR2A (0.46) HTR2AHTR2CHTR2BPTGS2TUBB4A
SCHEMBL15240817 0.83 TNKS2 (0.67) HTR2AHTR2CHTR2BTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107074777-A Benzyl alcohol derivatives, preparation method and therapeutic use thereof 赛诺菲 2017-08-18 CN claimed
EP-3746440-B1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME UNIV TEXAS (US) 2023-07-05 EP disclosed
EP-3746440-B1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME UNIV TEXAS (US) 2023-07-05 EP disclosed
US-11345659-B2 Pipecolic esters for inhibition of the proteasome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-05-31 US disclosed
US-11345659-B2 Pipecolic esters for inhibition of the proteasome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-05-31 US disclosed
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2021-01-07 US disclosed
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2021-01-07 US disclosed
EP-3746440-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME Board of Regents, The University of Texas System (US) 2020-12-09 EP disclosed
WO-2019152527-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-08-08 WO disclosed
WO-2019152527-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-08-08 WO disclosed
EP-0515514-A1 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS WHITBY RESEARCH, Inc. (US) 1992-12-02 EP disclosed
EP-0511879-A1 Pyrazine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-04 EP disclosed
US-5140015-A Racemic mixture for inducing an adenosine response in humans and animals WHITBY RESEARCH, INC. (US) 1992-08-18 US disclosed
US-5091531-A Antitumor agents BURROUGHS WELLCOME CO. (US) 1992-02-25 US disclosed
WO-1991013082-A1 2-ARALKOXY AND 2-ALKOXY ADENOSINE DERIVATIVES AS CORONARY VASODILATORS AND ANTIHYPERTENSIVE AGENTS WHITBY RESEARCH, INC. (US) 1991-09-05 WO disclosed
US-5037827-A Useful for treatment of disease caused by platelet activating factory EISAI CO., LTD. (JP) 1991-08-06 US disclosed
EP-0411150-A1 INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-06 EP disclosed
EP-0353474-A2 Glycerin derivative and its pharmacological use Eisai Co., Ltd. (JP) 1990-02-07 EP disclosed
CN-1031532-A HETEROCYCLIC COMPOUNDS WELLCOME FOUND (GB) 1989-03-08 CN disclosed
EP-0305093-A1 Imidazo(1,2-b)pyridazine derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1989-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345659-B2 Pipecolic esters for inhibition of the proteasome PSMG3, PSME3, PSMC1 HTR2A 4751/4885HTR2C 4470/4885HTR2B 4762/4885
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME PSMG3, PSME3, PSMC1 HTR2A 4751/4885HTR2C 4470/4885HTR2B 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.